Comparison of Premenopousal and Postmenopausal Breast Cancer Cases in Terms of Demographic and Prognostic Factor

İlker Kızıloğlu¹, Ahmet Çağdaş Acara^2, , Bahattin Bayar³, Serkan Karaıslı⁴, Erdem Sarı⁵ and Ercüment Tarcan⁴

¹Bozyaka Research and Training Hospital/ Surgent

²Department of Emergency Medicine, Sağlık Bilimleri University, Faculty of Medicine, Bozyaka Research and Training Hospital, İzmir, Turkey

³Muş State Hospital/ Surgent

⁴Katip Çelebi University Hospital/Surgent

⁵Biğadiç State Hospital / Surgent

Cite this paper:
İlker Kızıloğlu, Ahmet Çağdaş Acara, Bahattin Bayar, Serkan Karaıslı, Erdem Sarı and Ercüment Tarcan. Comparison of Premenopousal and Postmenopausal Breast Cancer Cases in Terms of Demographic and Prognostic Factor. Journal of Cancer Research and Treatment. 2018; 6(1):6-11. doi: 10.12691/jcrt-6-1-2

Abstract

Breast cancer is the second most common type of cancer in the world and it is the most frequently seen cancer type in women. In early stages involving small and monocenter tumors, surgical treatment with breast conserving surgery followed by radiotherapy is the most preferred treatment regimen. Similar to the size of the tumor, several prognostic factors determine survival in breast cancer patients. This study was conducted to evaluate prognostic factors and their relationship to the menopausal status of the patients. University Ataturk Training and Research Hospital, Izmir, Turkey with 573 patients diagnosed with breast cancer between January 2006 and December 2012. Patient age, menopausal status, tumor location surgical treatment information, treatment regimen was gathered using the registry system of the hospital. Male breast cancer patients and patients with insufficient data were excluded. The mean (±SD) age of the study population was determined as 55.9 (±12.9). Most of the patients (65.3%) included in the study were identified as post-menopausal (n=199). Post-menopausal women were detected with larger tumors (p=0.048), at a later stage (p=0.037), with higher KI-67 index (p=0.015) and received more adjuvant hormone therapy (p=0.036) when compared to the pre-menopausal women. Multi-centered studies are needed to evaluate prognostic factors and their relationship to the menopausal status of the patients in order to plan more precise personal treatment regimens.

Keywords:
breast cancer KI-67 menopausal status

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	IARC. IA for R on C WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Internet]. GLOBOCAN. 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?
[2]	Parkin DM. Global cancer statistics in the year 2000. Lancet Oncology. 2001; 533-43.
[3]	Gunderson LL, Tepper JE. Breast Cancer. In Clinical Radiation Oncology. Second Edi. Gunderson LL, Tepper JE, editors. Philadelphia: Elsevier; 2011. 1453 p.
[4]	Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50:7-33.
[5]	Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015 Nov 1;137(9): 2060-71.
[6]	Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010; 127: 2918-27.
[7]	Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004; 6: 229-39.
[8]	Ozmen V. Breast cancer in the World and Turkey. J Breast Heal. 2008; 4(2): 7-12.
[9]	Pirone JR, D’Arcy M, Stewart DA, Hines WC, Johnson M, et al. Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1735-44.
[10]	Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001; 51: 434-43.
[11]	Karagöz Özen DS, Ozturk MA, Aydin Ö, Turna ZH, Ilvan S, et al. Receptor expression discrepancy between primary and metastatic breast cancer lesions. Oncol Res Treat. 2014;37(11): 622-6.
[12]	Erdamar S. Meme Carcinomalarında Histolojik Tipler ve Prognoz. In: Unal G, Unal H, editors. Meme Hastaliklari. Nobel Tip Kitabevleri; 2001. p. 301-5.
[13]	Nouh MA, Ismail H, El-Din NHA, El-Bolkainy MN. Lymph node metastasis in breast carcinoma: clinicopathological correlations in 3747 patients. J Egypt Natl Canc Inst. 2004; 16(1): 50-6.
[14]	Kondov B, Kondov G, Spirovski Z, Milenkovikj Z, Colanceski R, et al. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1; 38(1): 81-90.
[15]	Cakir M, Tekin A, Kücükkartallar T, Vatansev C, Aksoy F, et al. Axillary lymph node status in multicentric breast tumors and breast tumors with nipple involvement. Breast Care (Basel). 2012 Oct; 7(5): 394-6.
[16]	Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, et al. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. J Clin Pathol. 2017 Apr 17. pii: jclinpath-2016-204304.
[17]	Benson JR, Jatoi I. Highlights of the San Antonio Breast Cancer Symposium 2016. Future Oncol. 2017 Jun 26.
[18]	Yun SJ, Sohn YM, Seo M. Risk Stratification For Axillary Lymph Node Metastases in Breast Cancer Patients: What Clinicopathological and Radiological Factors of Primary Breast Cancer Can Predict Preoperatively Axillary Lymph Node Metastases? Ultrasound Q. 2017 Mar; 33(1): 15-22.
[19]	Benson JR, Jatoi I. Highlights of the San Antonio Breast Cancer Symposium 2016. Future Oncol. 2017 Jun 26.